COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
Shared Solutions®
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Helping patients stay committed to their COPAXONE® therapy

Teva’s Shared Solutions® offers a full range of support services to help your patients stay the course and reach their COPAXONE® treatment goals

Teva-trained nurses

Reliable partners for your patients and your practice

Teva-trained nurses provide your patients with services to help them stay on track, including

Small Change, Big Difference

Teva-trained nurses can help encourage your patients to stay on therapy.

See Services Offered

Personalized communication from Teva’s Shared Solutions® helps to offer patients the support they need throughout their therapy experience

Teva’s Shared Solutions® gives personal attention to COPAXONE® patients — patients receive ongoing contact from the team at Shared Solutions® via email, mail, and phone, so you can be confident that they have support every step of the way.

Teva’s Shared Solutions® PLUS

Teva’s Shared Solutions® PLUS — Compliance and adherence support for the critical first 90 days on COPAXONE®

Teva understands that some patients may be at a higher risk of discontinuing therapy. That's why Teva’s Shared Solutions® PLUS provides extra high-touch support so that you can be reassured that these patients are feeling cared for.

Who can benefit most from Teva’s Shared Solutions® PLUS?

Characteristics that may present barriers to compliance/adherence include

COPAXONE iTracker®

A mobile tool to help patients track their injections

Teva’s Shared Solutions® presents the COPAXONE iTracker® — an app that lets patients manage their injection routines using their Apple or Android mobile devices.

With a customizable, user-friendly interface, the COPAXONE iTracker® allows patients to

  • Record and track injections, injection areas, and site and depth settings
  • Create a 3-times-a-week injection schedule that works for them
    • The COPAXONE iTracker® alerts patients when they forget to record an injection
  • Set injection and prescription refill reminders
  • Connect directly to a Teva’s Shared Solutions® nurse for support
  • Receive daily injection tips
  • Automatically sync data with COPAXONE webTrackerTM

Ask your patients to download COPAXONE iTracker® for their Apple® or Android™ mobile devices from the iTunes® App store or Google Play™ store

App Store icon Google play icon

More tracking tools

Teva’s Shared Solutions® cares about helping your patients stay on track with COPAXONE® that's why patients are offered innovative, interactive injection tracking tools to help them manage their injections and stay compliant.


The autoject ®2 for glass syringe helps patients to manage their COPAXONE® injections

  • Patients do not have to see the needle while injecting
  • COPAXONE® therapy is delivered at the touch of a button
  • The autoject®2 for glass syringe can be used with both 20 mg/mL and 40 mg/mL formulations

autoject® 2 for glass syringe
Not actual size.

The autoject®2 for glass syringe is available through Teva’s Shared Solutions® for free with a physician's prescription.

  • Free replacements with prescription
  • Designed for 1,000 injections or 3 years of use, whichever comes first1

Look for the blue plunger

Teva's 3-times-a-week COPAXONE® 40 mg can be identified by the blue plunger.

COPAXONE® 40 mg can be identified by the blue plunger
Not actual size.

Teva’s Shared Solutions® is committed to helping your patients find financial solutions to start and stay on their COPAXONE® treatment
Explore financial solutions
In-home initial injection trainings help support patients' injection experience
Learn more
Explore milestones in the development of COPAXONE® as an enduring option in relapsing MS care.


  1. COPAXONE® (glatiramer acetate injection) Current Prescribing Information. Teva Neuroscience, Inc.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.


COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site